Our technologies
![](https://ptxtherapeutics.com/wp-content/uploads/2020/05/group-10-1.png)
Cell therapy: OmniCAR
The OmniCAR platform seeks to overcome the challenges of conventional CAR-T therapy including manufacturing, safety and reliability. OmniCAR is a modular, universal CAR platform based on technology licensed from UPenn and Oxford University. It allows unprecedented control and flexibility over current generation CAR-T approaches.
![](https://ptxtherapeutics.com/wp-content/uploads/2020/05/icon-4.png)
Cell therapy: CellPryme
CellPryme is a high-performance cell therapy enhancement platform that can improve CAR-T efficacy. The CellPryme platform consists of two distinct components which can be used separately but have significant synergies when used together. CellPryme-M can be briefly added to standard manufacturing processes. CellPryme-A is used as an adjuvant alongside cellular immunotherapy.
![](https://ptxtherapeutics.com/wp-content/uploads/2020/05/icon-4.png)
Targeted therapy: PTX-100
PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme, thereby disrupting the oncogenic Ras pathway. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas, where it is showing encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T cell lymphomas.
![](https://ptxtherapeutics.com/wp-content/uploads/2018/03/our-science-bg.jpg)
Recent investor briefing
![](https://ptxtherapeutics.com/wp-content/uploads/2023/05/Frame-565.png)
Register for an upcoming briefing or watch a previous session.
OUR PIPELINE
We have a diversified pipeline of later stage and emerging assets developed with world-leading partners including Yale, UPenn, Oxford and Moffitt and Peter MacCallum Cancer Centre.
INVESTOR PORTAL
Here you will find ASX announcements and share price data, along with other key company information. You can also subscribe for email updates and online investor briefings to engage with management directly.
![](https://ptxtherapeutics.com/wp-content/uploads/2020/07/logo.png)
STAY UP TO DATE
Register your details to receive company updates from Prescient Therapeutics
Media
Prescient Therapeutics appoints accomplished medical professional Dr Gavin Shepherd as a director
4th Jul 2024
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), a clinical-stage oncology company developing personalised therapies for cancer, has appointed accomplished medical professional Dr Gavin Shepherd as an independent…
Prescient Therapeutics appoints accomplished medical professional Dr Gavin Shepherd as a director
4th Jul 2024
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), a clinical-stage oncology company developing personalised therapies for cancer, has appointed accomplished medical professional Dr Gavin Shepherd as an independent…
Prescient Therapeutics: Current Developments in Cancer Treatment
31st May 2024
Prescient Therapeutics, an ASX-listed company, is engaged in the development of drugs targeting various forms of cancer, with a specific focus on blood cancers that…
Prescient Therapeutics PTX-100 shows promising results in Phase 1b study
21st May 2024
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) CEO and managing director Steven Yatomi-Clarke sits down with Jonathan Jackson in the Proactive studio ahead of a presentation of the…
Prescient Therapeutics to present PTX-100 results at T-Cell Lymphoma Forum in California
20th May 2024
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has been invited to present PTX-100 Phase 1b results at the 15th Annual T-Cell Lymphoma Forum (TCLF) to be…